Cancer

117 studies in Cancer

  1. A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) Versus Docetaxel in Previously Treated Subjects With Non-Small Cell Lung Cancer
    1. Minnesota
  2. A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
    1. Minnesota
  3. A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
    1. Arizona,
    2. Florida,
    3. Minnesota
  4. A Phase I Study of the Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors
    1. Arizona,
    2. Florida,
    3. Minnesota
  5. A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma
    1. Arizona,
    2. Florida
  6. Mindfulness-Based Intervention in Breast Cancer Patients Undergoing Chemotherapy
    1. Minnesota
  7. Phase I Dose Finding/Phase II Placebo-Controlled Trial of Eltrombopag During Consolidation Therapy in Adults With Acute Myeloid Leukemia (AML) in Complete Remission
    1. Minnesota
  8. A Phase 1, Open-Label Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of Intradermally Administered ID-LV305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
    1. Minnesota
  9. A Randomized, Double-Blind Pilot Study of N-acetylcysteine Mucoadherent Rinse Versus Placebo for Thickened Secretions and Mucositis Secondary to Chemoradiotherapy in the Management of Head and Neck Malignancies
    1. Arizona,
    2. Minnesota
  10. Randomized Phase II Study of AB (Nab-paclitaxel [Abraxane™], Bevacizumab) Versus Ipilimumab for 1st Line Therapy of Unresectable Stage IV Metastatic Malignant Melanoma (BRAF V600E Negative)
    1. Minnesota
  1. Prev
  2. 5
  3. 6
  4. 7
  5. 8
  6. 9
  7. Next
Jan. 02, 2014

You Are ... The Campaign for Mayo Clinic

Mayo Clinic is a not-for-profit organization. Make a difference today.